Id4基因甲基化在恶性淋巴瘤中的检测意义

本研究探讨id4基因启动子区甲基化状态在非霍奇金淋巴瘤（NHL）患者中的检测意义。采用甲基化特异性聚合酶链反应（MS—PCR）对正常人和初诊NHL患者骨髓进行id4基因启动子区甲基化状况进行检测，同时进行骨髓穿刺和骨髓活检，并对患者进行随访。结果表明：id4基因在正常骨髓中呈完全性非甲基化状态。18例初治NHL患者中1例经骨髓活检证实有淋巴瘤骨髓受累，4例发现有id4基因甲基化。14例id4基因非甲基化的NHL患者在8个月随访期内病情稳定，再次检测骨髓未发现淋巴瘤骨髓受累，而1例id4基因甲基化伴骨髓受累的NHL患者在随访期间转变为白血病，3例id4基因甲基化伴无骨髓受累的NHL患者中2例在随访期间复查发现有骨髓受累。结论：在骨髓检查正常的NHL患者中检出id4基因甲基化可能提示淋巴瘤骨髓微量受累。

Significance of id4 Gene Promoter Methylation Detection in Lymphoma

The aim of this study was to evaluate the significance of id4 gene promotor methylation detection in NHL patients. MS-PCR method was used to detect the status of id4 gene methylation in health donors and newly diagnosed NHL patients. The results indicated that the id4 gene was unmethylated in bone marrow samples from health donors. Among 18 newly diagnosed NHL patients, including one NHL patient with bone marrow cells involved, 4 patients were found in id4 gene methylation by MS-PCR. The 14 patients with id4 gene unmethylation were in their stable status and no bone marrow involvement were found by bone marrow biopsy during the 8-month follow-up. During the follow-up, the patient with both bone marrow involvement and id4 gene methylation turned to leukemia, in 2 out of the 3 patients with id4 gene methylation but without bone marrow involvement at diagnosis, the bone marrow involvement was found at last. It is concluded that the id4 gene methylation may be an indicator for MRD in NHL patients without bone marrow involvement.